Browsing Tag
Inc.
380 posts
Can The Real Brokerage Inc. (NASDAQ: REAX) unlock scale and margins through its $880m RE/MAX Holdings, Inc. (NYSE: RMAX) deal
Find out how The Real Brokerage Inc.’s REMAX acquisition could reshape real estate technology, franchising and agent productivity.
Why anti-CD20 competition in multiple sclerosis is shifting toward real-world performance data
Discover why real-world data is reshaping anti-CD20 competition in MS and what it means for TG Therapeutics, Inc.’s BRIUMVI strategy. Read more.
How intranasal neurosteroids may change emergency care timing in mild traumatic brain injury
Can ONP-002 change concussion care timing? Discover how Oragenics, Inc. is targeting early intervention in mTBI treatment.
How United Community Banks, Inc. is using M&A to scale local market dominance with Peach State Bancshares, Inc.
United Community Banks, Inc. acquires Peach State Bancshares, Inc. in a $100M deal. Discover what this means for regional banking growth and consolidation.
What BWX Technologies, Inc.’s acquisition of Precision Components Group signals for U.S. nuclear manufacturing revival
Find out how BWX Technologies, Inc.’s acquisition of Precision Components Group is shaping U.S. nuclear manufacturing and future energy infrastructure.
Could Arlo Technologies (NYSE: ARLO) turn aging-in-place care into its next SaaS growth engine?
Arlo buys Aloe Care Health to enter aging-in-place services. Read how the deal could reshape Arlo’s SaaS growth story and smart home care strategy.
How QXO, Inc.’s $17bn TopBuild Corp. acquisition accelerates scale, margins, and vertical integration strategy
QXO, Inc.’s $17B TopBuild deal could reshape building products distribution. Discover how scale, margins, and integration drive its strategy.
United Bancshares (OTCQX: UBOH) lifts dividend after margin expansion powers Q1 2026 earnings
United Bancshares lifted profit, margins, and its dividend in Q1 2026. Read how buybacks, loan growth, and deposit momentum are reshaping the story.
Why AACR 2026 data on FT839 matters for hematologic cancer and autoimmune markets
Find out how Fate Therapeutics, Inc.’s FT839 could reshape CAR T economics and expand into autoimmune disease markets. Read the full analysis.
Why selective immune homeostasis is the bigger story behind CUE-401
Cue Biopharma’s CUE-401 data points to a bigger autoimmune story. Read why selective immune homeostasis could reshape immunology pipelines.